NCT02324803 2014-12-24
Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients
Southern China Urology Cancer Consortium
Phase 2 Unknown
Southern China Urology Cancer Consortium
University of Chicago
National Cancer Institute (NCI)